A Cochrane review included 42 studies with a total of 4 024 women on metformin. Metformin alone slightly improved live birth rate (see Table ), but not significantly in combination with clomiphene (OR 1.21, 95% CI 0.92 to 1.59; 9 trials, n=1079). Clinical pregnancy rates were improved for metformin versus placebo (Table ) and for metformin and clomiphene versus clomiphene alone (OR 1.59, 95% CI 1.27 to 1.99; 16 trials, n=1529).
| Outcome | Relative effect : OR (95% CI) | Assumed risk - control | Corresponding risk (95% CI) -metformin | Participants (studies) |
|---|---|---|---|---|
| Live birth rate | 1.59 (1.00 to 2.51) | 141 per 1000 | 208 per 1000 (141 to 292) | 435 (4) |
| Clinical pregnancy rate | 1.93 (1.42 to 2.64) | 110 per 1000 | 193 per 1000 (149 to 246) | 1027 (9) |
| Ovulation rate | 2.55 (1.81 to 3.59) | 2 00 per 1000 | 389 per 1000 (312 to 473) | 701 (14) |
| Miscarriage rate | 1.08 (0.50 to 2.35) | 40 per 1000 | 43per 1000 (20 to 89) | 748 (4) |
| Adverse events (gastrointestinal) | 4.76 (3.06 to 7.41) | 106 per 1000 | 362 per 1000 (267 to 469) | 670 (7) |
In the studies that compared metformin and clomiphene, there was evidence of an improved live birth rate (OR 0.3, 95% CI 0.17 to 0.52, 2 studies, n=500) and clinical pregnancy rate (OR 0.34, 95% 0.21 to 0.55, 2 studies, n=500) in the group of obese women who took clomiphene.
Metformin was associated with a significantly higher incidence of gastrointestinal disturbances than placebo .
Comment: The quality of evidence is downgraded by inconsistency (variability in results across studies) and by imprecise results (wide confidence intervals).
The following decision support rules contain links to this evidence summary: